338 related articles for article (PubMed ID: 24314750)
1. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Vimala PV; Bhutada PS; Patel FR
Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
[TBL] [Abstract][Full Text] [Related]
2. Agomelatine in depressive disorders: its novel mechanisms of action.
Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
[TBL] [Abstract][Full Text] [Related]
3. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
4. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light.
Tchekalarova J; Stoynova T; Ilieva K; Mitreva R; Atanasova M
Pharmacol Biochem Behav; 2018 Aug; 171():1-9. PubMed ID: 29807067
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine: An Astounding Sui-generis Antidepressant?
Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
[TBL] [Abstract][Full Text] [Related]
7. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
Guardiola-Lemaitre B; De Bodinat C; Delagrange P; Millan MJ; Munoz C; Mocaër E
Br J Pharmacol; 2014 Aug; 171(15):3604-19. PubMed ID: 24724693
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
9. Melatonergic drugs in clinical practice.
Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
[TBL] [Abstract][Full Text] [Related]
11. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
Pringle A; Bogdanovskaya M; Waskett P; Zacharia S; Cowen PJ; Harmer CJ
J Psychopharmacol; 2015 Oct; 29(10):1129-32. PubMed ID: 26174133
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.
Racagni G; Riva MA; Molteni R; Musazzi L; Calabrese F; Popoli M; Tardito D
World J Biol Psychiatry; 2011 Dec; 12(8):574-87. PubMed ID: 21999473
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
14. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
Millan MJ
Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT
Tchekalarova J; Kortenska L; Ivanova N; Atanasova M; Marinov P
Psychopharmacology (Berl); 2020 Feb; 237(2):503-518. PubMed ID: 31720718
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.
Soumier A; Banasr M; Lortet S; Masmejean F; Bernard N; Kerkerian-Le-Goff L; Gabriel C; Millan MJ; Mocaer E; Daszuta A
Neuropsychopharmacology; 2009 Oct; 34(11):2390-403. PubMed ID: 19571795
[TBL] [Abstract][Full Text] [Related]
17. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine targets a range of major depressive disorder symptoms.
Dubocovich ML
Curr Opin Investig Drugs; 2006 Jul; 7(7):670-80. PubMed ID: 16869122
[TBL] [Abstract][Full Text] [Related]
19. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Rainer Q; Xia L; Guilloux JP; Gabriel C; Mocaër E; Hen R; Enhamre E; Gardier AM; David DJ
Int J Neuropsychopharmacol; 2012 Apr; 15(3):321-35. PubMed ID: 21473810
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
